The United States has approved Lynparza's treatment of HRD-positive advanced ovarian cancer

olaparib, which includes AstraZeneta and Merca East, has been approved in the United States as a first-line maintenance treatment, using beva monoantigen to treat HRD-positive advanced ovarian cancer.The decision allows doctors to prescribe maintenance therapy for adult patients with advanced epitheliotic, fallopian tube, or primary peritiotic cancer who have a full or partial response to first-line platinum chemotherapy and whose cancer is associated with a homogenous recombinant defect (HRD) positive state defined by harmful or suspected harmful BRCA mutations and/or genomic instability.The license is based on a subgroup analysis of biomarkers from phase III PAOLA-1 trials, which showed that Limpazza combined beval monoantigen maintenance therapy reduced the risk of disease progression or death by 67 percent.Among HD-positive patients with advanced ovarian cancer, Lynparza's addition raised progressive lifetime (PFS) to a median of 37.2 months, while the single-use beva monoantin was 17.7 months, the company said.“ Ovarian cancer is a devastating disease. In the PAOLA-1 trial, the magnitude of benefits for HRD-positive patients was significant. The combination of Lynparza and bevacizumab now provides a new standard of care for women with hd-positive advanced ovarian cancer, and I look forward to seeing this translated into clinical practice.According to the results of the PAOLA-1 trial, the European Union, Japan and other countries are currently conducting a regulatory review of Limpaza.Enhertu's second breakthrough position in the U.S.At the same time, AstraZeneatic also announced Enhertu's second U.S. breakthrough treatment name for HER2-positive, non-excisive or metastatic gastric or gastroesophageal conjugation adenocarcinoma patients who have previously received two or more treatment options, including quercetin.“ Current treatment options are limited to HER2-positive metastatic gastric cancer patients and relapsed patients, and there are currently no approved HER2 targeted drugs. "We look forward to working with the U.S. Food and Drug Administration to further explore Enhertu's potential as an important new treatment and the first antibody drug binding for this devastating disease," said Jose Baselga, executive vice president of oncology research and development.AstraZeneta and AstraZeneta jointly develop and commercialize Enhertu globally, with the exception of Japan, which has exclusive rights. （cyy123.com）